Active, not recruitingPhase 3NCT01983241

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Grifols Therapeutics LLC
Intervention: Alpha-1 MP(biological)
Enrollment: 345 enrolled
Eligibility: 18-70 years · All sexes
Timeline: 2013 – 2027

Study locations (30)

Grifols Investigative Site, Phoenix, Arizona, United States
Grifols Investigative Site, Gainesville, Florida, United States
Grifols Investigative Site, Leesburg, Florida, United States
Grifols Investigative Site, Miami, Florida, United States
Grifols Investigative Site, St Louis, Missouri, United States
Grifols Investigative Site, Wilmington, North Carolina, United States
Grifols Investigative Site, Portland, Oregon, United States
Grifols Investigative Site, Hershey, Pennsylvania, United States
Grifols Investigative Site, Charleston, South Carolina, United States
Grifols Investigative Site, Tyler, Texas, United States
Grifols Investigative Site, Vicente López, Buenos Aires, Argentina
Grifols Investigative Site, Córdoba, Córdoba Province, Argentina
Grifols Investigative Site, Sydney, New South Wales, Australia
Grifols Investigative Site, Chermside, Queensland, Australia
Grifols Investigative Site, Adelaide, South Australia, Australia
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01983241 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency →

← Back to all trials